Australië - Engels - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - monobasic potassium phosphate, quantity: 136.1 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - indications as at 1 january 1991: treatment of severe hypophosphataemia (serum levels <0.3mmol/l) and other degrees of hypophosphataemia when oral therapy is not possible. lowering the ph of urine. the treatment of potassium depletion in patients with hypokalaemia; iv administration is indicated when the patient is unable to take potassium orally or if hypokalemia is severe.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - sodium chloride, quantity: 234 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - indications as at 01 january 1991 : as an additive to parenteral fluids in patients who have specific electrolyte needs for sodium or chloride ions. as a sclerosing agent for small symptomatic varicose veins.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - magnesium sulfate heptahydrate, quantity: 500 mg/ml - injection, concentrated - excipient ingredients: water for injections - indications as at 01 jan 1991 : parenteral administration of magnesium is indicated in the treatment of acute hypomagnesaemia. magnesium salts are also indicated to prevent hypomagnesaemia in patients receiving total parenteral nutrition. magnesium sulphate is also indicated in the prevention and treatment of life-threatening seizures in the treatment of toxemias of pregnancy (pre-eclampsia and eclampsia). for emegency treatment of some arrhythmias such as torsade de pointes and those associated with hypokalemia.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - potassium chloride, quantity: 223 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - indications as at 01 jan 1991 : the treatment of potassium depletion in patients with hypokalaemia; treatment of digitalis intoxication. iv administration is indicated when the patient is unable to take potassium orally or if hypokalaemia is severe.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - arginine hydrochloride, quantity: 600 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - indications as at 01 jan 1991 : arginine stimulates the release of growth hormone by the pituitary gland and may be used instead of , or in addition to, other tests such as insulin-induced hypoglycaemia, for the evaluation of growth disorders; false positive and false negative results are relatively common and evaluation therefore should not be made on the basis of a single arginine test. arginine is used as an acidifying agent in severe metabolic alkalosis. arginine is used in some conditions accompanied by hyperammonaemia stemming from inborn errors of the urea cycle, particularly where there is a severe deficiency of ornithine carbamoyl transferase or carbamoyl phosphate synthetase where respiratory alkalosis is present.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - calcium gluconate monohydrate, quantity: 95.3 mg/ml - injection, solution - excipient ingredients: calcium saccharate; water for injections - calcium gluconate is a calcium salt used primarily for the prevention and treatment of calcium deficiency. parenteral administation of calcium gluconate is needed in acute hypocalcaemia and hypocalcsemic tetany. it can be given intravenously in the treatment of severe hyper-kalaemia and in overdosage of magnesium sulphate, as calcium is the antagonist of magnesium toxicity. iv injections have been used in the treatment of acute renal biliary and intestinal colic. calcium has been used as an inotrope in cardiac resuscitation. they may also be used for the prevention of hypocalcaemia in exchange transfusions, and in long term electrolyte replacement therapy.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - zinc chloride, quantity: 5.3 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid - indications as at 01 jan 1991 : zinc chloride injection is intended for use as an additive to compatible intravenous fluids or total parenteral nutrition solutions. it is indicated for the prevention and treatment of zinc deficiency, which may be characterised by growth deterioration, skin lesions, alopecia, impaired reproductive development and function, and delayed or inhibited wound healing. indications as at 01 jan 1991 : zinc chloride injection is intended for use as an additive to compatible intravenous fluids or total parenteral nutrition solutions. it is indicated for the prevention and treatment of zinc deficiency, which may be characterised by growth deterioration, skin lesions, alopecia, impaired reproductive development and function, and delayed or inhibited wound healing.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - sodium selenate decahydrate, quantity: 467 microgram (equivalent: selenium, qty 100 microgram) - injection, intravenous infusion - excipient ingredients: water for injections - indications as at 01 march 1998 : this formulation is indicated for use as a supplement to iv solutions given for tpn. administation of the solution in tpn solutions helps to maintain plasma levels of copper, manganese, and selenium and to prevent depletion of endogenous stores of these trace elements and subsequent deficiency symptoms. cancer: prophylaxis of malignant neoplasms via selenium supplementation.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - sodium selenate decahydrate, quantity: 111 microgram (equivalent: selenium, qty 24 microgram) - injection, intravenous infusion - excipient ingredients: water for injections - indications as at 01 march 1998 : this formulation is indicated for use as a supplement to iv solutions given for tpn. administation of the solution in tpn solutions helps to maintain plasma levels of copper, manganese, and selenium and to prevent depletion of endogenous stores of these trace elements and subsequent deficiency symptoms. cancer: prophylaxis of malignant neoplasms via selenium supplementation.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - glucose, quantity: 500 mg/ml - injection, intravenous infusion - excipient ingredients: hydrochloric acid; water for injections; sodium bicarbonate - glucose 50% intravenous infusion is strongly hypertonic and may be used to reduce increased cerebrospinal pressure and/or oedema due to delirium tremens or acute alcoholic intoxication. it may also be used to treat severe hypoglycaemia due to an excess of insulin and to provide concentrated calories in total parenteral nutrition regimes.